OSUR · XBRL financial data

Orasure Technologies financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OSUR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	171,721	233,674	387,479	405,472	185,827	115,021
Cost of goods and services sold	69,853	116,074	239,842	233,820	106,437	66,823
Gross profit	101,868	117,600	147,637	171,652	79,390	48,198
Research and development	31,032	34,170	36,237	33,728	26,047	42,528
General and administrative	42,653	50,328	68,206	58,191	46,215	47,677
Total operating expenses	107,045	127,764	170,594	138,968	107,640	120,167
Operating income (loss)	(5,177)	(10,164)	(22,957)	32,684	(28,250)	(71,969)
Interest income	—	—	1,569	5,862	11,469	8,078
Other income (expense)	1,653	872	6,481	23,574	(380)	229
Income tax expense (benefit)	11,398	13,706	1,458	2,603	1,799	1,801
Net income (loss)	(14,922)	(22,998)	(17,934)	53,655	(19,500)	(68,731)
Earnings per share, basic USD per share	(0.22)	(0.32)	(0.25)	0.73	(0.26)	(0.94)
Earnings per share, diluted USD per share	(0.22)	(0.32)	(0.25)	0.72	(0.26)	(0.94)
Weighted average shares, basic thousands of shares	67,505	71,981	72,505	73,348	74,434	73,485
Weighted average shares, diluted thousands of shares	67,505	71,981	72,505	74,389	74,434	73,485

Fiscal years (OSUR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	160,802	116,762	83,980	290,407	267,763	199,278
Short-term investments	48,599	36,279	26,867	0	—	—
Accounts receivable	38,835	45,323	70,797	40,171	23,816	22,203
Inventory	31,863	53,138	96,232	47,614	34,197	31,060
Total current assets	288,893	288,431	325,718	386,459	333,220	261,908
Property and equipment, net	51,860	88,164	59,413	45,420	45,105	39,179
Right-of-use asset	4,461	9,056	10,399	12,270	13,442	11,996
Goodwill	40,351	40,279	35,104	35,696	40,330	43,363
Total assets	454,472	460,990	444,708	482,845	479,659	403,168
Accounts payable	17,407	28,024	39,349	13,151	8,173	6,521
Accrued liabilities	22,227	33,778	—	—	—	—
Total current liabilities	46,489	68,064	70,392	39,536	33,483	39,795
Lease liability, non-current	3,591	7,202	9,101	11,162	12,321	10,870
Total liabilities	55,901	80,457	81,084	52,174	69,321	62,341
Accumulated deficit	(97,455)	(120,453)	(138,387)	(83,931)	(103,431)	(172,162)
Total stockholders' equity	398,571	380,533	363,624	430,671	410,338	340,827
Total liabilities and equity	454,472	460,990	444,708	482,845	479,659	403,168
Common shares outstanding (cover page) thousands of shares	71,946	72,305	73,245	73,796	74,800	69,126

Fiscal years (OSUR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(14,922)	(22,998)	(17,934)	53,655	(19,500)	(68,731)
Stock-based compensation	7,139	7,807	11,622	10,729	11,920	10,147
Depreciation and amortization	9,387	11,658	15,308	20,936	10,872	10,192
Net cash from operating activities	5,807	(35,382)	(47,202)	141,583	27,374	(49,023)
Purchases of property and equipment	26,674	36,622	6,774	5,802	3,797	4,197
Net cash from investing activities	(14,029)	(5,501)	21,085	66,154	(39,026)	(6,810)
Proceeds from issuing common stock	95,036	—	—	—	—	—
Share repurchases	2,088	2,113	2,254	1,901	3,548	15,040
Net cash from financing activities	92,479	(2,817)	(3,828)	(3,023)	(4,176)	(16,944)
Net change in cash	85,087	(44,040)	(32,782)	206,427	(22,644)	(68,485)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Orasure Technologies	160,582	30,639	(9,921)*	69.0M	16.2 quarters	Q2 FY26 10-QJun 30, 2026
Tactile Systems Technology	75,110	91,858	11,978*	22.4M	—	Q3 FY26 10-QSep 30, 2026
Electromed	20,450	19,417*	2,994*	8.4M	—	Q4 FY26 10-KJun 30, 2026
Cerus	16,350	57,714	3,007*	202.0M	—	Q3 FY26 10-QSep 30, 2026
SANUWAVE Health	9,376	9,739	425*	8.6M	—	Q2 FY26 10-QJun 30, 2026
Inogen	87,276	95,084	2,946*	26.5M	—	Q2 FY26 10-QJun 30, 2026
Bioventus	30,709	142,442	20,658*	not reported	—	Q3 FY26 10-QSep 26, 2026
Treace Medical Concepts	12,610	45,376	(4,698)*	65.0M	9.7 quarters	Q2 FY26 10-QJun 30, 2026
SS Innovations International	13,647	not reported	(4,235)*	200.4M	3.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.